Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-12-17 Purchase | 2024-12-18 08:27 am | NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chairman and Chief Scientist 10% Owner | 40,000 | $1.17 | $46,800 | 1,516,834 (Indirect Direct) | View |
| 2023-08-30 Purchase | 2023-09-11 09:19 am | NRX Pharmaceuticals Inc. | NRXP | Gorovitz Aaron Director | 35,000 | $0.3199 | $11,197 | 105,000 (Indirect) | View |
| 2023-08-30 Purchase | 2023-09-11 09:15 am | NRX Pharmaceuticals Inc. | NRXP | Hurvitz Chaim Director | 70,000 | $0.2875 | $20,125 | 2,214,793 (Indirect Direct) | View |
| 2023-08-23 Purchase | 2023-08-24 12:14 pm | NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Scientist 10% Owner | 100,000 | $0.33 | $33,000 | 14,768,329 (Indirect Direct) | View |
| 2023-08-22 Purchase | 2023-08-23 09:24 am | NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Scientist 10% Owner | 200,000 | $0.322 | $64,400 | 14,668,329 (Indirect Direct) | View |
| 2022-12-16 Purchase | 2022-12-19 07:14 am | NRX Pharmaceuticals Inc. | NRXP | Willard Stephen H CHIEF EXECUTIVE OFFICER | 50,000 | $1.17 | $58,500 | 50,000 (Direct) | View |
| 2022-12-16 Purchase | 2022-12-19 07:09 am | NRX Pharmaceuticals Inc. | NRXP | VAN VOORHEES SETH CHIEF FINANCIAL OFFICER | 30,000 | $1.1 | $33,000 | 46,337 (Direct) | View |
| 2022-11-25 Purchase(A) | 2022-12-19 07:08 am | NRX Pharmaceuticals Inc. | NRXP | VAN VOORHEES SETH CHIEF FINANCIAL OFFICER | 16,337 | $1.115 | $18,215 | 16,337 (Direct) | View |
| 2022-12-07 Sale | 2022-12-09 4:33 pm | NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Director 10% Owner | 400,000 | $1 | $400,000 | 14,468,329 (Indirect Direct) | View |
| 2022-11-29 Sale | 2022-12-01 7:29 pm | NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner | 22,171 | $1.5043 | $33,352 | 9,634,793 (Indirect) | View |
| 2022-11-28 Purchase | 2022-11-29 07:00 am | NRX Pharmaceuticals Inc. | NRXP | Flynn Patrick John Director | 11,750 | $1.2479 | $14,663 | 41,959 (Indirect Direct) | View |
| 2022-11-25 Purchase | 2022-11-28 07:42 am | NRX Pharmaceuticals Inc. | NRXP | VAN VOORHEES SETH CHIEF FINANCIAL OFFICER | 16,337 | $1.115 | $18,215 | 16,377 (Indirect) | View |
| 2022-11-16 Purchase(A) | 2022-11-23 4:09 pm | NRX Pharmaceuticals Inc. | NRXP | Hurvitz Chaim Director | 500,000 | $1.0298 | $514,905 | 500,000 (Direct) | View |
| 2022-11-16 Purchase | 2022-11-21 5:58 pm | NRX Pharmaceuticals Inc. | NRXP | Hurvitz Chaim Director | 500,000 | $1.0298 | $514,905 | 2,525,876 (Indirect Direct) | View |
| 2022-11-16 Sale | 2022-11-18 7:05 pm | NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner | 166,737 | $1.0264 | $171,138 | 9,656,964 (Indirect) | View |
| 2022-11-11 Sale | 2022-11-15 7:40 pm | NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner | 49,200 | $1.0063 | $49,510 | 9,823,701 (Indirect) | View |
| 2022-07-29 Sale | 2022-08-02 5:43 pm | NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner | 784,063 | $1.0094 | $791,433 | 9,872,901 (Indirect) | View |
| 2022-06-03 Sale | 2022-06-07 8:11 pm | NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner | 445,712 | $0.68185 | $303,910 | 12,656,964 (Indirect) | View |
| 2022-06-01 Purchase(A) | 2022-06-02 09:46 am | NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Scientist 10% Owner | 100,000 | $0.58 | $58,000 | 14,868,329 (Indirect Direct) | View |
| 2022-06-01 Purchase | 2022-06-02 08:55 am | NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Scientist 10% Owner | 100,000 | $58 | $5,800,000 | 14,868,329 (Indirect Direct) | View |
| 2021-08-23 Sale | 2021-11-02 4:05 pm | NRX Pharmaceuticals Inc. | NRXP | Daigneault Alessandra General Counsel & Secretary | 33,715 | $13.11 | $442,004 | 308,591 (Direct) | View |
| 2021-09-15 Sale | 2021-11-02 4:04 pm | NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Chief Comm. & Patient Officer | 40,000 | $11.76 | $470,400 | 307,200 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
Ownership | 2024-06-26 7:37 pm | N/A 2027-06-14 | NRX Pharmaceuticals Inc. | NRXP | McBride Dennis Director | 0 | $0 | 6,320 (Direct) | View |
| 2022-12-14 Ownership | 2023-02-14 5:14 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Director 10% Owner | 300,000 | $0 | 14,468,329 (Indirect) | View |
| 2022-10-21 Option Award | 2022-11-22 5:46 pm | N/A 2032-10-21 | NRX Pharmaceuticals Inc. | NRXP | Gorovitz Aaron Director | 162,660 | $0 | 162,660 (Direct) | View |
| 2022-10-21 Option Award | 2022-11-22 5:45 pm | N/A 2032-10-21 | NRX Pharmaceuticals Inc. | NRXP | Glied Sharon Director | 162,660 | $0 | 228,097 (Direct) | View |
| 2022-10-21 Option Award | 2022-11-22 5:44 pm | N/A 2032-10-21 | NRX Pharmaceuticals Inc. | NRXP | Flynn Patrick John Director | 162,660 | $0 | 162,660 (Direct) | View |
| 2022-10-21 Option Award | 2022-11-21 5:58 pm | N/A 2032-10-21 | NRX Pharmaceuticals Inc. | NRXP | Hurvitz Chaim Director | 162,660 | $0 | 2,525,876 (Direct) | View |
Ownership | 2022-07-22 4:27 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Willard Stephen H Chief Executive Officer | 0 | $0 | 1,000,000 (Direct) | View |
| 2022-07-01 Gift | 2022-07-05 5:06 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner | 2,000,000 | $0 | 10,656,964 (Indirect) | View |
Ownership | 2022-06-29 6:14 pm | 2023-06-13 2032-06-12 | NRX Pharmaceuticals Inc. | NRXP | VAN VOORHEES SETH Chief Financial Officer | 0 | $0 | 325,000 (Direct) | View |
Ownership | 2022-03-24 6:25 pm | 2023-03-15 2032-03-14 | NRX Pharmaceuticals Inc. | NRXP | Strassberg Ira S Chief Financial Officer | 0 | $0 | 425,000 (Direct) | View |
| 2022-03-08 Option Award | 2022-03-10 4:04 pm | N/A 2032-03-08 | NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Interim CEO | 100,000 | $2.61 | 347,200 (Direct) | View |
| 2021-08-26 Option Award | 2021-11-02 4:07 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | McMaster Herbert Raymond Director | 10,424 | $0 | 45,086 (Direct) | View |
| 2021-08-26 Conversion | 2021-11-02 4:07 pm | N/A 2028-01-04 | NRX Pharmaceuticals Inc. | NRXP | McMaster Herbert Raymond Director | 28,724 | $2.22 | 45,086 (Direct) | View |
| 2021-08-26 Exercise | 2021-11-02 4:07 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | McMaster Herbert Raymond Director | 18,300 | $2.22 | 45,086 (Direct) | View |
| 2021-07-16 Gift | 2021-11-02 4:06 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Javitt Daniel C. 10% Owner | 434,594 | $0 | 13,102,676 (Indirect) | View |
| 2021-08-19 Conversion | 2021-11-02 4:05 pm | N/A 2030-09-01 | NRX Pharmaceuticals Inc. | NRXP | Daigneault Alessandra General Counsel & Secretary | 92,582 | $3.07 | 308,591 (Direct) | View |
| 2021-08-19 Option Award | 2021-11-02 4:05 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Daigneault Alessandra General Counsel & Secretary | 33,603 | $0 | 308,591 (Direct) | View |
| 2021-08-19 Exercise | 2021-11-02 4:05 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Daigneault Alessandra General Counsel & Secretary | 58,979 | $3.07 | 308,591 (Direct) | View |
| 2021-08-16 Option Award | 2021-11-02 4:04 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Chief Comm. & Patient Officer | 36,290 | $0 | 307,200 (Direct) | View |
| 2021-08-16 Exercise | 2021-11-02 4:04 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Chief Comm. & Patient Officer | 63,710 | $0.2 | 307,200 (Direct) | View |
| 2021-08-16 Conversion | 2021-11-02 4:04 pm | N/A 2026-03-01 | NRX Pharmaceuticals Inc. | NRXP | Besthof Robert Chief Comm. & Patient Officer | 100,000 | $0.2 | 307,200 (Direct) | View |
Ownership | 2021-11-02 4:03 pm | N/A 2028-01-04 | NRX Pharmaceuticals Inc. | NRXP | McMaster Herbert Raymond Director | 0 | $0 | 48,931 (Direct) | View |
| 2021-05-24 Option Award | 2021-06-10 6:48 pm | N/A 2028-04-01 | NRX Pharmaceuticals Inc. | NRXP | Troy Daniel Director | 108,530 | $0 | 108,530 (Direct) | View |
| 2021-05-24 Option Award | 2021-06-10 6:48 pm | N/A N/A | NRX Pharmaceuticals Inc. | NRXP | Javitt Jonathan C Chief Executive Officer 10% Owner | 14,817,329 | $0 | 1,468,332 (Direct) | View |